Immunovant, Inc. (IMVT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は New York City, NY, アメリカ. 現CEOは Eric Venker.
IMVT を有する IPO日 2019-06-21, 362 名の正社員, に上場 NASDAQ Global Select, 時価総額 $5.4B.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies to treat autoimmune diseases. The company's lead candidate, batoclimab, is a fully human monoclonal antibody that selectively inhibits the neonatal fragment crystallizable receptor and is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials recently initiated for warm autoimmune hemolytic anemia. Founded in 2018 and headquartered in New York, Immunovant operates as a subsidiary of Roivant Sciences Ltd.
